据公告信息所示，广峰胶囊主营业务为空心胶囊的制造与销售，其核心产品明胶空心胶囊已通过国家药 品监督管理局药品审评中心技术审评，并在CDE原料药、药用辅料和药包材登记信息公示平台中显 示"与制剂共同审评审批结果"为"A"状态。 公告称，本次交易完成后，华兰股份将与广峰胶囊在客户资源方面实现协同共享，并依托自身在药包材 领域的合规管理能力、质量控制体系及客户资源优势，助力广峰胶囊持续提升产品质量、扩大业务规 模。 智通财经APP讯，华兰股份(301093.SZ)公告，公司近日与宁波广峰胶囊有限公司(简称"广峰胶囊")、宁 波斯普康生物技术有限公司(简称"宁波斯普康")签署了《关于宁波广峰胶囊有限公司之股份转让协 议》。同时，华兰股份与广峰胶囊、宁波斯普康、陈明耀签署了《关于宁波广峰胶囊有限公司之股东协 议》。本次华兰股份将使用自有资金人民币846.47万元购买宁波斯普康在广峰胶囊持有的35.00%股权。 交易完成后，华兰股份持有广峰胶囊35.00%股权，在2026年至2028年期间，华兰股份有权根据协议约 定进一步收购广峰胶囊16%至35%的股权，届时持股比例将提升至51%至70%，从而实现对广峰胶囊的 控股。 ...

Company Overview - Huangshan Capsule Co., Ltd. is located in Anhui Province and was established on August 12, 1996, with its listing date on October 25, 2016 [2] - The company specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [2] - The revenue composition includes gelatin hollow capsules (64.54%), enteric-coated gelatin hollow capsules (19.22%), and plant capsules and others (16.24%) [2] Stock Performance - As of September 23, the stock price of Huangshan Capsule decreased by 2.01% to 7.32 CNY per share, with a total market capitalization of 2.189 billion CNY [1] - Year-to-date, the stock price has increased by 18.16%, but it has seen a decline of 5.91% over the last five trading days, 9.85% over the last 20 days, and 1.88% over the last 60 days [2] Financial Performance - For the period from January to June 2025, Huangshan Capsule achieved a revenue of 244 million CNY, representing a year-on-year growth of 3.66% [2] - The net profit attributable to the parent company was 35.55 million CNY, showing a year-on-year increase of 19.78% [2] Shareholder Information - As of June 30, 2025, the number of shareholders was 17,900, a decrease of 2.57% from the previous period [2] - The average circulating shares per person increased by 2.64% to 16,197 shares [2] - The company has distributed a total of 125 million CNY in dividends since its A-share listing, with 62.81 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) held 1.6367 million shares, an increase of 129,400 shares from the previous period [3] - Nu'an Multi-Strategy Mixed A Fund (320016) entered as a new shareholder, holding 1.3943 million shares [3]

Core Insights - The company participated in a collective reception day and mid-year performance briefing on September 19, 2023, aimed at enhancing communication with investors [1] - The company is focusing on evidence-based research in oncology and cardiovascular treatment, exploring clinical value and conducting post-market evaluations [1] - The company is developing new compounds based on existing products and is engaged in research for new indications through innovation and research system development [1] Product Development and Market Strategy - The company is working on the development of improved new drugs and upgrading existing products based on its product reserves [1] - Collaborations with research institutions are being pursued to advance the development of chemical drugs, traditional Chinese medicine, and health products [1] - The company’s subsidiary, Guizhou Guangdeli Pharmaceutical Co., Ltd., exports products such as gelatin capsules and plant-based capsules to various regions, including North America and Europe, starting in 2024 [2] Export and Revenue Insights - In the first half of 2025, the subsidiary achieved export revenue of 1,833,947.39 yuan, accounting for 0.19% of the company's total revenue [2] - Due to tariff issues, the subsidiary plans to suspend exports to the United States starting in 2025 [2] - Currently, there are no additional overseas market expansion plans beyond existing operations [2]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over thirty years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of August 19, the company's stock closed at 8.06 yuan, with a PE ratio of 45.69, compared to the industry average of 59.49 and the industry median of 40.19 [1][2] - The total market capitalization of Huangshan Capsule is 2.411 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - Huangshan Capsule's stock closed at 8.18 yuan, up 1.11%, with a rolling PE ratio of 46.37 times and a total market capitalization of 2.447 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 times and a median of 39.08 times, placing Huangshan Capsule at the 84th position in the industry ranking [1] - As of the first quarter of 2025, only one institution holds shares in Huangshan Capsule, with a total of 18,000 shares valued at 0.00 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [1] - The company is one of the earliest manufacturers of medicinal hollow capsules in China, boasting over 30 years of high-quality production history [1] - Huangshan Capsule has a strong reputation in the medicinal hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the company stands at 29.26% [2] Industry Comparison - Huangshan Capsule's PE (TTM) is 46.37, compared to the industry average of 55.70 and the industry median of 39.08 [2] - The company’s market capitalization is 2.447 billion yuan, while the industry average market capitalization is 11.731 billion yuan [2]

Core Viewpoint - Huangshan Capsule's stock closed at 8.19 yuan on August 4, with a 1.74% increase, and a rolling PE ratio of 46.43, marking a new low in 373 days, with a total market value of 2.45 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90%, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule's PE ratio of 46.43 is below the industry average of 54.31 and the industry median of 38.11, ranking 84th in the medical device sector [1][2] - The company’s market value stands at 2.45 billion yuan, compared to the industry average market value of 11.617 billion yuan [2] Capital Flow - On August 4, the net inflow of main funds into Huangshan Capsule was 764,500 yuan, although the overall trend over the past five days showed a net outflow of 4.3336 million yuan [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, with over 30 years of high-quality production history [1] - The company is one of the earliest manufacturers of pharmaceutical hollow capsules in China and has a high reputation in the industry [1] Financial Performance - For Q1 2025, the company reported operating revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year [2] - The sales gross margin for the same period was 29.26% [2] Market Position - The company's current price-to-earnings (PE) ratio is 44.84, compared to the industry average of 54.89 and the industry median of 37.06 [2] - Huangshan Capsule's total market capitalization is 2.366 billion yuan [1] Industry Context - The medical device industry, where Huangshan Capsule operates, has an average PE ratio of 54.89 and a median of 37.06 [2] - Huangshan Capsule ranks 83rd in terms of PE ratio within its industry [1] Capital Flow - On July 31, the company experienced a net outflow of main funds amounting to 2.725 million yuan, with a total outflow of 3.7357 million yuan over the past five days [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of July 16, the company's stock closed at 7.76 yuan, with a PE ratio of 43.99, marking a new low in 353 days, and a total market capitalization of 2.321 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.87, with a median of 37.48, placing Huangshan Capsule at the 84th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huangshan Capsule was 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.23 yuan on June 24, with a 2.55% increase, resulting in a rolling PE ratio of 40.98 times and a total market value of 2.162 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% with a sales gross margin of 29.26% [2] - The company's PE ratio (TTM) stands at 40.98, while the industry average is 49.12, and the industry median is 36.07 [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the medical device industry average PE at 49.12 and the median at 36.07 [1][2] - The company has received several accolades, including the "Anhui Famous Brand Product" for its "Jingchuan" brand gelatin hollow capsules and recognition as an excellent product brand in the pharmaceutical excipients sector [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.41 yuan, up 1.51%, with a rolling PE ratio of 42.00, marking a new low in 325 days, and a total market value of 2.216 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the average PE ratio for the medical device industry at 50.64 and the median at 37.05 [2] - The average market value of the industry is 10.91 billion yuan, while Huangshan Capsule's market value is 2.216 billion yuan [2] Shareholder Information - As of March 31, 2025, Huangshan Capsule had 18,378 shareholders, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]